Selank-Amidate

Selank-Amidate is a chemically stabilized derivative of Selank, a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro; TKPRPGP) patterned on tuftsin, a naturally occurring immunomodulatory tetrapeptide derived enzymatically from IgG. C-terminal amidation replaces the free carboxylic acid with a carboxamide group, shielding the peptide from carboxypeptidase-mediated hydrolysis and extending estimated plasma half-life from roughly 20-30 minutes (unmodified Selank) to approximately 2-4 hours, supporting less frequent dosing without reported alteration of receptor binding affinity.

Pharmacological mechanisms established for the parent compound, and by extension attributed to the amidated form, include:

• Allosteric modulation of GABA-A receptors, upregulating subunit gene expression in hippocampus and prefrontal cortex without direct channel-gating activity comparable to benzodiazepines.

• Dose-dependent inhibition of plasma enkephalin-degrading enzymes including aminopeptidase N and dipeptidyl peptidase IV (IC50 approximately 15 microM), prolonging endogenous opioid peptide activity without direct opioid receptor binding.

• Region-specific enhancement of serotonin turnover (elevated 5-HIAA ratios in hypothalamus and brainstem) and normalization of dopamine and noradrenaline metabolism under stress conditions.

• Upregulation of brain-derived neurotrophic factor (BDNF) in rat hippocampus following intranasal administration, supporting neuroplasticity.

• Immunomodulatory activity inherited from its tuftsin lineage, including suppression of IL-6 gene expression and modulation of Th1/Th2 cytokine balance.

No published pharmacological studies have specifically characterized Selank-Amidate as a distinct chemical entity. All mechanistic claims for the amidated form are inferred from research on unmodified Selank.

The entire published clinical evidence base belongs to unmodified Selank, not to the amidated derivative. No human or animal trials have been conducted using Selank-Amidate as a specific test compound.

For Selank, the principal human study is a comparative trial (Zozulia et al., 2008, Zh Nevrol Psikhiatr Im S S Korsakova) enrolling 62 patients with generalized anxiety disorder or neurasthenia randomized to intranasal Selank or the benzodiazepine medazepam. Outcomes on the Hamilton Anxiety Rating Scale, Zung Self-Rating Anxiety Scale, and Clinical Global Impression were comparable between arms. Selank additionally produced antiasthenic effects and increased serum leu-enkephalin half-life that correlated inversely with symptom severity, with no sedation, cognitive impairment, or dependence observed. Uchakina et al. (2008; PMID 18577961) examined 14 days of Selank in patients with anxiety-asthenic disorders, reporting significant IL-6 gene expression suppression in peripheral blood cells and cytokine balance shifts. Russian registration trials enrolling an aggregate reported to exceed 800 patients supported approval of Selank for GAD and neurasthenia in Russia and Ukraine in 2009; most primary publications appear in Russian-language journals and lack English-language accessibility.

In rodent studies, Volkova et al. (2016; PMC4757669; DOI 10.3389/fphar.2016.00031) found intranasal Selank at 300 mcg/kg altered expression of 45 GABAergic system genes one hour post-dose in 30 male Wistar rats, with a strong positive correlation (r=0.86) between Selank and GABA gene-expression profiles. Kasian et al. (2017; PMID 28280289) showed that Selank combined with diazepam produced an 8.9-fold greater open-arm time on the elevated plus maze versus saline in a 14-day chronic mild stress rat model (n=48), suggesting additive or synergistic anxiolysis. Zozulya et al. (2001; PMID 11550013) established dose-dependent inhibition of plasma enkephalin hydrolysis at IC50 approximately 15 microM, exceeding the inhibitory potency of the reference inhibitors bacitracin and puromycin.

No efficacy or pharmacokinetic data exist for the amidated form.

Typical dosage: 250-500 mcg (daily).

No clinical trials have established dosing parameters for Selank-Amidate. The following reflects two distinct sources: the registered prescribing information for unmodified Selank in Russia, and conventions reported in the compounding and research-peptide community for the amidated form.

Registered Selank (Russia): 0.15% intranasal solution, approximately 2 drops per nostril three times daily (approximately 75 mcg per drop, totaling roughly 900 mcg per day) for up to 14 days. Russian clinical trials employed doses up to 2700 mcg per day divided across three daily administrations for periods up to 21 days, followed by a rest period of one to three weeks before re-dosing.

Selank-Amidate (community and research-peptide use, not clinically validated): The extended half-life attributed to C-terminal amidation is reported to support once- or twice-daily dosing rather than three times daily. Ranges commonly described in the research community are 200-600 mcg per dose administered via intranasal spray or subcutaneous injection, once or twice daily. Typical cycle duration is 10-14 days followed by a washout of 1-3 weeks. Rodent preclinical studies used intranasal doses of 300 mcg/kg daily; subcutaneous models ranged 0.5-1.0 mg/kg.

No official dosing guidelines exist for Selank-Amidate. This information is provided for educational purposes only and does not constitute medical advice. Selank-Amidate has not been approved by the FDA or any Western regulatory authority; use should occur only under appropriate medical supervision.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most commonly described combination in the nootropic community is Selank or Selank-Amidate paired with Semax, a separate Russian-origin neuropeptide. The proposed rationale is complementary activity: Semax is associated with cognitive activation and BDNF upregulation, while Selank provides anxiolytic and GABAergic balance, theoretically producing focused cognitive engagement without stress reactivity. This pairing has no controlled clinical evidence and is entirely anecdotal.

Selank combined with diazepam was evaluated in a rat chronic mild stress model (Kasian et al., 2017; PMID 28280289). Combined administration produced an 8.9-fold increase in open-arm time on the elevated plus maze compared to saline controls, exceeding either agent alone. The authors proposed Selank may enhance benzodiazepine receptor affinity. This preclinical finding has not been translated to human trials, and combining any peptide with scheduled anxiolytics carries uncharacterized risks.

Community protocols additionally describe adding BPC-157 for putative neuroprotective and gut-brain axis effects, or stacking with other cognitive peptides. All such multi-peptide combinations are anecdotal, carry no supporting human data, and involve interaction profiles that remain entirely uncharacterized.

Selank-Amidate is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very well-tolerated

The safety profile in the published literature belongs to unmodified Selank; no independent safety data exist for the amidated derivative.

In Russian clinical trials, Selank was generally well tolerated. The most frequently reported adverse effect is mild transient nasal mucosal irritation in approximately 5-10% of patients receiving intranasal formulations. Nasal cavity discoloration has been described in approximately 10% of users. Less common events include mild headache, dysgeusia (metallic taste), and a modest glucose elevation in diabetic patients (approximately 7.4%). No sedation, psychomotor slowing, cognitive impairment, or clinically meaningful withdrawal syndrome was observed in comparative trials against benzodiazepines. No dependence or tolerance escalation was reported across published clinical or preclinical studies.

Preclinical acute toxicity studies report an LD50 exceeding 1000 mg/kg, indicating a wide therapeutic index relative to therapeutic doses. Chronic preclinical exposure over 28-90 days produced no adverse hematological, biochemical, or histopathological findings.

A theoretical concern of GABAergic receptor desensitization with extended use has been raised but has not been confirmed in published data. Selank-Amidate carries additional uncertainty for three reasons: the amide modification and any co-present N-acetyl group may generate metabolite profiles not yet characterized; long-term Western-population safety data are entirely absent; and no controlled drug-interaction studies have been performed with psychiatric or neurological medications. Use during pregnancy, breastfeeding, or in pediatric populations has not been evaluated. Patients with known hypersensitivity to peptide sequences or intranasal excipients should avoid this compound.